Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REaKT-SD: ECT vs. Ketamine for Acute Suicidal Depression
NCT06034821Phase 4Enrolling by invitation
- Sponsor
- Brigham and Women's Hospital
- Start
- Oct 2023
- Primary completion
- Oct 2030
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, single-blind trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Scale for Suicidal Ideation at 6 weeks. Started Oct 2023; status: enrolling by invitation.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06034821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034821.